Related Experiment Video
Updated: Dec 17, 2025
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes
Pier Vitale Nuzzo1,2,3, Jacob E Berchuck1,2, Keegan Korthauer4,5
1Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Abstract:
Improving early cancer detection has the potential to substantially reduce cancer-related mortality. Cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) is a highly sensitive assay capable of detecting early-stage tumors. We report accurate classification of patients across all stages of renal cell carcinoma (RCC) in plasma (area under the receiver operating characteristic (AUROC) curve of 0.99) and demonstrate the validity of this assay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).
